ARIAD Pharmaceuticals, Inc. ARIA today announced enrollment of fifty
percent of the patients planned in its randomized Phase 3 trial of Iclusig^®
(ponatinib) in adult patients with newly diagnosed chronic myeloid leukemia
(CML). The trial, formally known as EPIC (Evaluation of Ponatinib versus
Imatinib in Chronic Myeloid Leukemia), is designed to provide definitive
clinical data to support regulatory approval of ponatinib in treatment-naïve
CML patients.
An interim analysis of efficacy -- focused on the primary endpoint of major
molecular response rate (MMR) at twelve months -- will be performed in the
third quarter of 2014 based on the patients enrolled to date. Approximately
264 patients have been enrolled in the EPIC trial, and full patient enrollment
of approximately 500 patients in the trial is anticipated by the end of 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in